Pfizer taps Effector Therapeutics for its anticancer translation inhibitor

Pfizer taps Effector Therapeutics for its anticancer translation inhibitor

Effector’s eIF4E inhibitor is designed to halt the output of cancer-driving mutations in the PI3K pathway

  • 0 Likes

  • 0 Comments